<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105412</url>
  </required_header>
  <id_info>
    <org_study_id>1421</org_study_id>
    <nct_id>NCT05105412</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas</brief_title>
  <official_title>A Single Arm，Phase Ib/II Study of the Combination of Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or&#xD;
      refractory PTCL patients. Patients will be treated with the combination of lenalidomide and&#xD;
      gemcitabine until disease progression, intolerable toxicity, or patient withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 3000 newly diagnosed lymphoma patients in Taiwan, and T-cell neoplasms accounted&#xD;
      for 17.4% of total lymphomas. Peripheral T-cell lymphomas (PTCL) are heterogeneous&#xD;
      malignancies, and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS),&#xD;
      angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL) are the&#xD;
      most common subtypes.&#xD;
&#xD;
      Patients with relapsed or refractory PTCL to 1st-line chemotherapy had dismal prognosis under&#xD;
      conventional chemotherapy. Combination of gemcitabine with platinum chemotherapy may be&#xD;
      effective regimens, because they provided objective response rate (ORR) of 70% in PTCL&#xD;
      patients. Since most salvage chemotherapy regimens provided limited activity in PTCL, many&#xD;
      new regimens were studied in PTCL. Except brentuximab vedotin provided high activity through&#xD;
      targeting CD30 on ALCL, new regimens (including lenalidomide) provided ORR about 20% and PFS&#xD;
      about 3 months in PTCL.&#xD;
&#xD;
      Lenalidomide is an immunomodulatory agent, and it reduces T-regulatory cells, activates&#xD;
      CD8-positive T cells, and increases natural killer cell numbers and in activation status.&#xD;
      Gemcitabine may augment immune responses in several ways: activating T cells, increasing the&#xD;
      amount of dendritic cells, increasing the amounts of antigens loaded onto antigen-presenting&#xD;
      cells, and down-regulating T-regulatory cells. We design this phase 2 study under the&#xD;
      hypothesis of synergistic effect of anti-tumor immunity and efficacy to PTCL in combination&#xD;
      with lenalidomide and gemcitabine. The dose of lenalidomide monotherapy to treat PTCL is 25&#xD;
      mg daily based on previous studies, and we also start this dose in our study initially.&#xD;
      Lenalidomide in combination with gemcitabine in 1st-line treatment of patients with advanced&#xD;
      pancreatic cancer were studied before. Patients could tolerate oral lenalidomide of 25 mg&#xD;
      daily on days 1 to 21, and intravenous gemcitabine dose of 1000 mg/m2 on days 1, 8, and 15,&#xD;
      of each 28-day cycle. Because our enrolled patients will receive previous-line chemotherapy&#xD;
      and combination of lenalidomide and gemcitabine may exacerbate myelosuppression, we designed&#xD;
      oral lenalidomide of 25 mg daily on days 1 to 14, and intravenous gemcitabine dose of 1000&#xD;
      mg/m2 on days 1 and 8, of each 21-day cycle. In order to monitor toxicities and adjust drug&#xD;
      doses closely, we arrange phase Ib study to evaluate dose-limiting toxicities about&#xD;
      combination of lenalidomide and gemcitabine. The schedules about dose delays and&#xD;
      modifications were also designed in phase Ib and II studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the dose-limited toxicity (DLT) of combination of lenalidomide and gemcitabine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the objective response rate of combination of lenalidomide and gemcitabine by Lugano classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24months</time_frame>
    <description>To evaluate the progression free survival of combination of lenalidomide and gemcitabine by Lugano classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>24months</time_frame>
    <description>To evaluate the overall survival of combination of lenalidomide and gemcitabine by Lugano classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>24months</time_frame>
    <description>To evaluate the number of participants with treatment-related adverse events assessed by CTCAE v 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Peripheral T-cell Lymphomas (PTCL)</condition>
  <arm_group>
    <arm_group_label>Lenalidomide and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide and Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and Gemcitabine (Dose level 11)</intervention_name>
    <description>lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8</description>
    <arm_group_label>Lenalidomide and Gemcitabine</arm_group_label>
    <other_name>Dose level 11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and Gemcitabine (Dose level 21)</intervention_name>
    <description>lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8</description>
    <arm_group_label>Lenalidomide and Gemcitabine</arm_group_label>
    <other_name>Dose level 21</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and Gemcitabine (Dose level 31)</intervention_name>
    <description>lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8</description>
    <arm_group_label>Lenalidomide and Gemcitabine</arm_group_label>
    <other_name>Dose level 31</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and Gemcitabine (Dose level 41)</intervention_name>
    <description>lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8</description>
    <arm_group_label>Lenalidomide and Gemcitabine</arm_group_label>
    <other_name>Dose level 41</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Adult patients (20 years of age) have the following three subtypes of PTCL:&#xD;
&#xD;
        (1)Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), (2)Angioimmunoblastic&#xD;
        lymphoma (AITL), or (3)Anaplastic large cell lymphoma (ALCL). If patients had CD30-positive&#xD;
        systemic ALCL, they should receive brentuximab vedotin before enrollment 2. (1) In&#xD;
        transplant-eligible patients: patients who have relapsed disease after autologous stem-cell&#xD;
        transplantation (2) In transplant-ineligible patients: patients who have received at least&#xD;
        first-line systemic chemotherapy treatment and have a stable disease, progressive disease,&#xD;
        or relapsed disease.&#xD;
&#xD;
        3. Patients have an ECOG Scale of Performance Status score of 0-1. 4. Patients have at&#xD;
        least one measurable lesion by CT with a size of &gt; 1.5 cm in at least one axis.&#xD;
&#xD;
        5. Patients have adequate renal function: serum creatinine (Cr) ≤ 1.5 times the upper limit&#xD;
        of normal range (ULN) and calculated creatinine clearance (Ccr) ≥ 40 mL/min.&#xD;
&#xD;
        6. Patients have adequate bone marrow function:&#xD;
&#xD;
          1. Absolute neutrophil count (ANC) ≥ 1500/μL, Without growth factor support (filgrastim&#xD;
             or lenograstim) for at least 14 days&#xD;
&#xD;
          2. Platelet count ≥ 75 000/μL. Evaluated at least 7 days after last platelet transfusion&#xD;
&#xD;
          3. Hemoglobin ≥ 8 g/dL. May receive transfusion 7. Patients have adequate hepatic&#xD;
             function: serum alkaline phosphatase (ALP), alanine, or aspartate aminotransferase&#xD;
             levels (ALT &amp; AST) ≤ 2.5 times the ULN and serum total bilirubin ≤ 1.5 times the ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have already been exposed to lenalidomide and gemcitabine.&#xD;
&#xD;
          2. Patients have less than 100 days from previous autologous stem cells transplantation&#xD;
             prior to first study drug dose.&#xD;
&#xD;
          3. Patients have HIV infection.&#xD;
&#xD;
          4. Patients have cerebral or meningeal disease including signs or symptoms of progressive&#xD;
             multifocal leukoencephalopathy.&#xD;
&#xD;
          5. Patients have symptomatic neurologic disease compromising normal activities of daily&#xD;
             living or requiring medication.&#xD;
&#xD;
          6. Patients have any active systemic viral, bacterial, or fungal infection requiring&#xD;
             systemic antibiotics within 2 weeks prior to first study drug dose.&#xD;
&#xD;
          7. Patients received prior immunosuppressive chemotherapy, therapeutic radiation, or any&#xD;
             immunotherapy (eg, immunoglobulin replacement, other monoclonal antibody therapies)&#xD;
             within 4 weeks of first study drug dose.&#xD;
&#xD;
          8. Patients have known hypersensitivity to any excipient contained in the drug&#xD;
             formulation of lenalidomide or gemcitabine.&#xD;
&#xD;
          9. Patients have known positive hepatitis B surface antigen but not receive&#xD;
             anti-hepatitis B drug, or known or suspected active hepatitis B and C infection.&#xD;
&#xD;
         10. Patients have diagnosed or treated for another malignancy within 3 years before the&#xD;
             first dose or previously diagnosed with another malignancy and have any evidence of&#xD;
             residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any&#xD;
             type are not excluded if they have undergone complete resection.&#xD;
&#xD;
         11. Patients have any of the following cardiovascular conditions or values within 6 months&#xD;
             before the first dose of study drug:&#xD;
&#xD;
               -  A left-ventricular ejection fraction &lt;50%.&#xD;
&#xD;
               -  Myocardial infarction within 2 years of randomization.&#xD;
&#xD;
               -  New York Heart Association (NYHA) Class III or IV heart failure&#xD;
&#xD;
               -  Evidence of current uncontrolled cardiovascular conditions, including cardiac&#xD;
                  arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic&#xD;
                  evidence of acute ischemia or active conduction system abnormalities.&#xD;
&#xD;
         12. Patients with unstable medical or psychiatric conditions or a history of any other&#xD;
             serious medical disease deemed inappropriate for inclusion in this study, as&#xD;
             determined by the investigators.&#xD;
&#xD;
         13. Women who are pregnant or breastfeeding or have a positive pregnancy test during&#xD;
             screening or Day 1 before the first dose of study drug.&#xD;
&#xD;
         14. Women of childbearing potential who do not use two effective contraceptive methods&#xD;
             from the time of signing informed consent through 6 months after the last dose of&#xD;
             study drug or agree to completely abstain from heterosexual intercourse.&#xD;
&#xD;
         15. Male patients, even if surgically sterilized, (i.e., status post vasectomy) who do not&#xD;
             agree to practice effective barrier contraception during the entire study period and&#xD;
             through 6 months after the last dose of study drug, or agrees to completely abstain&#xD;
             from heterosexual intercourse.&#xD;
&#xD;
         16. Patients with a life expectancy of &lt;3 months, as determined by the investigators.&#xD;
&#xD;
         17. Patients with, as judged by the investigators, other contraindications for&#xD;
             lenalidomide and gemcitabine administration, such as concurrent usage of drugs that&#xD;
             may have potentially severe drug-drug interactions.&#xD;
&#xD;
         18. Patients who are unwilling or unable to give consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsang-Wu Liu</last_name>
    <role>Study Director</role>
    <affiliation>Taiwan Cooperative Oncology Group, NHRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bor-Rong Chen</last_name>
    <phone>886-2-26534401</phone>
    <phone_ext>25162</phone_ext>
    <email>brong@nhri.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei-Li Ma</last_name>
    <phone>886-2-23123456</phone>
    <email>excellent0667@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital, Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Tsai-Yun Chen</last_name>
      <email>teresa@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Tsai-Yun Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ya-Ting Hsu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ya-Ping Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sin-Syue Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui-Jen Tsai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei-Li Ma, MD</last_name>
      <email>excellent0667@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wei-Li Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Hsin Kuo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Yao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shang-Ju Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tai-Chung Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia-Hau Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chieh-Lung Cheng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral T-cell lymphomas (PTCL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

